Chemoradiation for Locally Advanced, Unresectable NSCLC: New Standard of Care, Emerging Strategies

ONCOLOGY

Volumn 13, Issue 8, 1999, Pages 1075-1088

  Gordon, Gary S ^b   Vokes, Everett E ^a  

^a SECTION OF HEMATOLOGY ONCOLOGY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; GEMCITABINE; IRINOTECAN; LOMUSTINE; NAVELBINE; PACLITAXEL; VINBLASTINE; VINDESINE;

CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; ESOPHAGITIS; FOLLOW UP; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MULTIMODALITY CANCER THERAPY; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; REVIEW; SURVIVAL RATE; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DOSE FRACTIONATION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; META-ANALYSIS; NEOPLASM STAGING; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; SURVIVAL ANALYSIS;

EID: 0032823488     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (85)

1. Landis SH, Murray T, Bolden S, et al: Cancer statistics, 1998. CA Cancer J Clin 48, 6-29, 1998.
2. Ginsberg RJ, Vokes EE, Raben A: Non-small cell lung cancer, in Devita VT, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practices of Oncology, 5th ed, pp 858-911. Philadelphia, Lippincott-Raven, 1997.
3. American Society of Clinical Oncology: Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. J Clin Oncol 15:2996-3018, 1997.
4. Dillman RO, Seagren SL, Propert KJ, et al: A randomized trial of induction chemotherapy plus high-dose radiation vs radiation alone in stage III non-small-cell lung cancer. N Engl J Med 323:940-945, 1990.
5. Dillman RO, Herndon J, Seagren SL, et al: Improved survival of stage III non-small-cell lung cancer: Seven-year follow-up of Cancer and Leukemia Group B (CALGB) 8433 trial. J Natl Cancer Inst 88:1210-1215, 1996.
6. Sause WT, Scott C, Taylor S, et al: Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Group (ECOG) 4588: Preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst 87:198-205, 1995.
7. Komaki R, Scott CB, Sause WT, et al: Induction cisplatin/vinblastine and irradiation vs irradiation in unresectable squamous cell lung cancer: Failure patterns by cell type in RTOG 8808/ECOG 4588. Int J Radiat Oncol Biol Phys 39:537-544, 1997.
8. Sause W, Kolesar P, Taylor D, et al: Five year results: Phase III trial of regionally advanced unresectable non-small-cell lung cancer, RTOG 8808,ECOG 4588, SWOG 8992 (abstract). Proc Am Soc Clin Oncol 17:453a, 1998.
9. LeChevalier T, Arriagada R, Quiox E, et al: Radiotherapy alone vs combined chemotherapy and radiotherapy in non-resectable non-small-cell lung cancer: First analysis of a randomized trial in 353 patients. J Natl Cancer Inst 83:417-423, 1991.
10. LeChevalier T, Arriagada R, Quiox E, et al: Radiotherapy alone vs combined chemotherapy and radiotherapy in unresectable non-small-cell lung carcinoma. Lung Cancer (10;suppl 1):S239-244, 1994.
11. LeChevalier T, Arriagada R, Baldeyrou P, et al: Combined chemotherapy (vindesine, lomustine, cisplatin, and cyclophosphamide) and radical radiotherapy in inoperable nonmetastatic squamous cell carcinoma of the lung. Cancer Treat Rep 69:469-472, 1985.
12. Arriagada R, LeChevalier T, Rekacewicz E, et al: Cisplatin-based chemoradiotherapy (CT) in patients with locally advanced non-small-cell lung cancer (NSCLC): Late analysis of a French randomized trial (abstract). Proc Am Soc Clin Oncol 16:446a, 1997.
13. Mattson K, Holsti LR, Holsti P, et al: Inoperable non-small-cell lung cancer: Radiation with or without chemotherapy. Eur J Cancer Clin Oncol 24:477-482, 1988.
14. Van Houtte P, Klastersky J, Renaud A, et al: Induction chemotherapy with cisplatin, etoposide and vindesine before radiation therapy for non-small-cell lung cancer: A randomized study. Antibiot Chemother 41:131-137, 1988.
15. Crino L, Latini P, Meacci M, et al: Induction chemotherapy plus high-dose radiotherapy vs radiotherapy alone in locally advanced unresectable non-small-cell lung cancer. Ann Oncol 4:847-851, 1993.
16. Planting A, Helle P, Drings P, et al: A randomized study of high-dose split course radiotherapy preceded by high dose chemotherapy vs high-dose radiotherapy only in locally advanced non-small-cell lung cancer: The EORTC Lung Cancer Cooperative Group trial. Ann Oncol 7:139-144, 1996.
17. Morton RF, Jett JR, McGinnis WL, et al: Thoracic radiation therapy alone compared with combined chemoradiotherapy for locally advanced unresectable non-small-cell lung cancer: A randomized phase III trial. Ann Intern Med 115:681-686, 1991.
18. Non-small cell lung cancer collaborative group: Chemotherapy in non-small-cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J 311:899-909, 1995.
19. Marino P, Preatoni A, Cantoni A: Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb non-small-cell lung cancer. Cancer 76:593-601, 1995.
20. Pritchard RS, Anthony SP. Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small-cell lung cancer: A meta-analysis. Ann Intern Med 125:723-729, 1996.
21. Vokes E, Weichselbaum R: Concomitant chemoradiotherapy: Rational and clinical experience in patients with solid tumors. J Clin Oncol 8:911-934, 1990.
22. Schaake-Koning C, van den Bogaert W, Dalesio O: Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 326:524-530, 1992.
23. Soresi E, Clerici M, Grilli R, et al: A randomized clinical trial comparing radiation therapy vs radiation therapy plus cis-dichlorodiamine platinum (II) in the treatment of locally advanced non-small-cell lung cancer. Semin Oncol 25(6; suppl 7):20-25, 1988.
24. Trovo MG, Minatel E, Franchin G, et al: Radiotherapy vs radiotherapy enhanced by cis-platin in stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 24:11-15, 1992.
25. Blanke C, Ansari R, Mantravadi R, et al: Phase III trial of thoracic irradiation with or without cisplatin for locally advanced unresectable non-small-cell lung cancer: A Hoosier Oncology Group protocol. J Clin Oncol 13:1425-1429, 1995.
26. Mantravadi RVP, Sandler A, Montebello J, et al: Randomized phase III study of cisplatin (P) and vinblastine (V) followed by thoracic radiotherapy with or without hydroxyurea (HX) in previously untreated limited unresctable non-small-cell lung cancer (NSCLC): A Hoosier Oncology Group (HOG) study (abstract). Proc Am Soc Clin Oncol 17:454a, 1998.
27. Albain KS, Rusch VW, Crowley JJ, et al: Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: Mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol 13:1880-1982, 1995.
28. Albain KS, Crowley JJ, Turrisi AT, et al: Concurrent cisplatin/etoposide plus radiotherapy for pathologic stage IIIB non-small-cell lung cancer: A Southwest Oncology Group phase II study (S9019) (abstract). Proc Am Soc Clin Oncol 16:446a, 1997.
29. Furuse K, Fukuoka M, Takada Y, et al: A randomized phase III study of concurrent vs sequential thoracic radiotherapy in combination with mitomycin, vindesine and cisplatin in unresectable stage III non-small-cell lung cancer: Preliminary analysis (abstract). Proc Am Soc Clin Oncol 16:459a, 1997.
30. Furuse K, Fukuoka M, Takada Y, et al: Phase III study of concurrent vs sequential thoracic radiotherapy (TRT) in combination with mitomycin (M), vindesine (V), and cisplatin (P) in unresectable stage III non-small-cell lung cancer (NSCLC): Five-year median follow-up results (abstract). Proc Am Soc Clin Oncol 18:458a, 1999.
31. Saunders M, Dische S, Barrett A, et al: Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: A randomized multicenter trial. Lancet 350:161-165, 1997.
32. Bailey AJ, Parmar MKB, Stephens RJ, et al: Patient-reported short-term and long-term physical and psychological symptoms: Results of the continuous hyperfractionated accelerated radiotherapy (CHART) randomized trial in non-small-cell lung cancer. J Clin Oncol 16:3082-3093, 1998.
33. Mehta MP, Tannehill SP, Adak S, et al: Phase II trial of hyperfractionated accelerated radiation therapy for nonresectable non-small-cell lung cancer: Results of Eastern Cooperative Oncology Group 4593. J Clin Oncol 16:3518-3523, 1998.
34. Byhardt RW, Scott CB, Ettinger DS, et al: Concurrent hyperfractionated irradiation and chemotherapy for unresectable non-small-cell lung cancer: Results of Radiation Therapy Oncology Group 90-15. Cancer 75:2337-2344, 1995.
35. Lee JS, Scott C, Komaki R, et al: Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small-cell lung cancer: Radiation Therapy Oncology Group protocol 91-06. J Clin Oncol 14:1055-1064, 1996.
36. Komaki R, Scott C, Lee JS, et al: Impact of adding concurrent chemotherapy to hyperfractionated radiotherapy for locally advanced non-small-cell lung cancer (NSCLC): Comparison of RTOG 83-11 and RTOG 91-06. Am J Clin Oncol 20:435-440, 1997.
37. Komaki R, Scott C, Ettinger D, et al: Ran domized study of chemotherapy/radiation therapy combinations for favorable patients with locally advanced inoperable non-small-cell lung cancer: Radiation Therapy Oncology Group (RTOG) 92-04. Int J Radiat Oncol Biol Phys 38:149-155, 1997.
38. Bonomi P: Carboplatin in non-small-cell lung cancer: Review of the Eastern Cooperative Oncology Group trial and comparison with other carboplatin trials. Semin Oncol 18:2-7, 1991.
39. Green MR, Kreisman H, Doll DC, et al: Carboplatin in non-small-cell lung cancer: An update on the Cancer and Leukemia Group B experience. Semin Oncol 19(suppl 2):44-49, 1992.
40. Bishop JF, Ball DL, Smith JG, et al: A randomized phase III trial of concurrent carboplatin and twice daily radiotherapy in locally advanced non-small-cell lung cancer (abstract). Proc Am Soc Clin Oncol 17:464a, 1998.
41. Jeremic B, Shibamoto Y, Acimovic L, et al: Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer. J Clin Oncol 13:452-458, 1995.
42. Jeremic B, Shibamoto Y, Acimovic L, et al: Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/ etoposide for stage III non-small-cell lung cancer: A randomized study. J Clin Oncol 14:1065-1070, 1996.
43. Lau DH, Crowley JJ, Gandara DR, et al: Southwest Oncology Group phase II trial of concurrent carboplatin, etoposide, and radiation for poor-risk stage III non-small-cell lung cancer. J Clin Oncol 16:3078-3081, 1998.
44. Herbst RS, Dang NH, Skarin AT. Chemotherapy for advanced non-small-cell lung cancer. Hematol Oncol Clin North Am 11:473-517, 1997.
45. Choy H, Akerley W, Devore R: Paclitaxel, carboplatin and radiation therapy for non-small-cell lung cancer. Oncology 12(1;suppl 2):80-86,1998.
46. Choy H, Akerley W, Safran H, et al: Phase II trial of weekly paclitaxel and concurrent radiation therapy for locally advanced non-small-cell lung cancer (abstract). Proc Am Soc Clin Oncol 15:371, 1996.
47. Choy H, Akerley W, Safran S, et al: Multi-institutional phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer. J Clin Oncol 16:3316-3322, 1998.
48. Choy H, DeVore RD, Hande KR, et al: Phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small-cell lung cancer: A Vanderbilt Cancer Center Affiliate Network (VCCAN) trial (abstract). Proc Am Soc Clin Oncol 17:467a, 1998.
49. Belani CP, Aisner J, Day R, et al: Weekly paclitaxel and carboplatin with simultaneous thoracic radiotherapy for locally advanced non-small-cell lung cancer: Three year follow-up (abstract). Proc Am Soc Clin Oncol 16:448a, 1997.
50. Greco FA, Stroup SL, Gray JR, et al: Paclitaxel in combination chemotherapy with radiotherapy in patients with unresectable stage III non-small-cell lung cancer. J Clin Oncol 14:1642-1648, 1996.
51. Wagner H, Antonia SJ, Williams CC, et al: Concurrent paclitaxel/cisplatin with thoracic radiation in patients with stage IIIA/B non-small-cell lung cancer (abstract). Proc Am Soc Clin Oncol 16:448a, 1997.
52. Choy H, Akerley W, Safran H, et al: Phase I trial of outpatient weekly paclitaxel and concurrent radiation therapy for advanced non-small-cell lung cancer. J Clin Oncol 12:2682-2686, 1994.
53. Wagner H, Antonia S, Shaw G, et al: Induction chemotherapy with carboplatin and paclitaxel followed by hyperfractionated accelerated radiation for patients with unresectable stage IIIA and IIIB non-small-cell lung cancer (abstract). Proc Am Soc Clin Oncol 17:469a, 1998.
54. Wolf M, Faoro C, Goerg C, et al: Paclitaxel and simultaneous radiation in the treatment of stage III A/B non-small-cell lung cancer. Semin Oncol 23(suppl 16):108-112, 1996.
55. Lau DH, Ryu JK, Gandara DR, et al: Twice-weekly paclitaxel and radiation for stage III non-small-cell lung cancer. Semin Oncol 24(suppl 12):S12-106-S12-109, 1997.
56. Comella G, Frasci G, Scoppa G, et al: Weekly paclitaxel/cisplatin with concurrent radiotherapy in patients with locally advanced non-small-cell lung cancer: A phase I study. Semin Oncol 24(suppl 12):S12-113-S12-116, 1997.
57. Hudes R, Langer C, Movsas B, et al: Induction paclitaxel and carboplatin followed by concurrent chemoradiotherapy in unresectable, locally advanced non-small-cell lung carcinoma: Report of FCCC 94-001 (abstract). Proc Am Soc Clin Oncol 16:448a, 1997.
58. Rosenthal DI, Okani O, Corak J, et al: Seven-week continuous-infusion paclitaxel plus concurrent radiation therapy for locally advanced non-small-cell lung cancer: A phase I study. Semin Oncol 24(suppl 12):S12-96-S12-100, 1997.
59. Niell HB, Miller AA, Kumar P, et al: Phase I/II trial of paclitaxel, cisplatin and radiation therapy for stage III non-small-cell lung cancer (abstract). Proc Am Soc Clin Oncol 16:447a, 1997.
60. Meyer JT, Spencer SA, Jennelle RL, et al: Phase I study of concurrent Taxol/cisplatin with thoracic radiation in locally advanced non-small-cell lung cancer (abstract). Proc Am Soc Clin Oncol 15:372, 1996.
61. Rathmann J, Rigas JR, Leopold KA, et al: Daily paclitaxel and thoracic radiation therapy for the treatment of stage II and III non-small-cell lung cancer (abstract). Proc Am Soc Clin Oncol 16:478a, 1997.
62. Socinski MA, Clark J, Halle J, et al: Induction carboplatin/paclitaxel followed by concurrent carboplatin/paclitaxel and dose-escalating thoracic conformai radiation therapy in stage III non-small-cell lung cancer: A phase I/II trial (abstract). Proc Am Soc Clin Oncol 17:500a, 1998.
63. Vokes EE, Leopold KA, Herndon JE, et al: A CALGB randomized phase [I study of gemcitabine or paclitaxel or vinorelbine with cisplatin as induction chemotherapy and concomitant chemoradiotherapy in stage IIIB non-small-cell lung cancer (NSCLC): Feasibility data (CALGB study #9431) (abstract). Proc Am Soc Clin Oncol 16:455a, 1997.
64. 62a. Vokes EE, Leopold KA, Herndon JE, et al: A randomized phase II study of gemcitabine or paclitaxel or vinorelbine with cisplatin as induction chemotherapy (Ind CT) and concomitant chemoradiotherapy (XRT) for unresectable stage III non-small-cell lung cancer (NSCLC) (CALBG study 9431) (abstract). Proc Am Soc Clin Oncol 18:459a, 1999.
65. Mauer AM, Masters GA, Haraf DJ, et al: Phase I study of docetaxel and concomitant thoracic radiation therapy. J Clin Oncol 16:159-164, 1998.
66. Teng M, Choy H, DeVore RD, et al: Phase I trial of outpatient weekly docetaxel and concurrent therapy for stage III unresectable non-small-cell lung cancer: A Vanderbilt Cancer Center Affiliate Network (VCCAN) trial (abstract). Proc Am Soc Clin Oncol 17:503a, 1998.
67. Koukourakis MI, Kourousis C, Androulakis N, et al: Accelerated radiotherapy and weekly docetaxel for non-small-cell lung cancer: A dose escalation phase I/II study (abstract). Proc Am Soc Clin Oncol 16:472a, 1997.
68. Depierre A, Chasting C, Quiox E, et al: Vinorelbine vs vinorelbine plus cisplatin in advanced NSCLC: A randomized trial. Oncology 5:37-42, 1994.
69. Edelstein MP, Wolfe LA, Dutch DS: Potentiation of radiotherapy by Navelbine (NVB) in a human non-small-cell lung cancer (NSCLC) line (abstract). Proc Am Assoc Cancer Res 36:611, 1995.
70. Masters GA, Haraf DJ, Hoffman, PC, et al: Phase I study of vinorelbine, cisplatin, and concomitant thoracic radiation in the treatment of advanced chest malignancies. J Clin Oncol 16:2157-2163, 1998.
71. Zatloukal P, Petruzelka L, Zemanova M, et al: Vinorelbine (VRL) plus cisplatin (CDDP) and concurrent radiotherapy in advanced non-small-cell lung cancer (abstract). Proc Am Soc Clin Oncol 17:505a, 1998.
72. Abratt RP, Sandler A, Crino L, et al: Combined cisplatin and gemcitabine for non-small-cell lung cancer: Influence of scheduling on toxicity and drug delivery. Semin Oncol 25(suppl 9):35-43, 1998.
73. Castellano D, Lianes P, Paz-Ares L, et al: A phase II study of a novel gemcitabine plus cisplatin regimen administered every 3 weeks for advanced non-small-cell lung cancer. Ann Oncol 9:457-459, 1998.
74. Vokes EE, Gregor A, Turrisi AT: Gemcitabine and radiation therapy for non-small-cell lung cancer. Semin Oncol 25(suppl 9):66-69, 1998.
75. Scalliet P, Goor C, Galdermans D, et al: Gemzar (gemcitabine) with thoracic radiotherapy-a phase II pilot study in chemonaive patients with advanced non-small-cell lung cancer (NSCLC) (abstract). Proc Am Soc Clin Oncol 17:499a, 1998.
76. Fukuoka M, Nitani H, Sukuki A, et al: A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol 10:16-20, 1992.
77. Yokoyama A, Kurita Y, Saijo N, et al: Dose-finding study of irinotecan and cisplatin plus concurrent radiotherapy for unresectable stage III non-small-cell lung cancer. Br J Cancer 78:257-262, 1998.
78. Saka H, Shimokata K, Yoshida S, et al: Irinotecan (CPT-11) and concurrent radiotherapy in locally advanced non-small-cell lung cancer (NCSLC): A phase II study of Japan Clinical Oncology Group (JCOG9504) (abstract). Proc Am Soc Clin Oncol 16:447a, 1997.
79. Nakagawa K, Yamamoto S, Kudoh S, et al: Irinotecan (CPT-11) and carboplatin (CBDCA) with concurrent thoracic radiotherapy (TRT) for unresectable, stage III non-small-cell lung cancer (NSCLC)-Preliminary results (abstract). Proc Am Soc Clin Oncol 17:496a, 1998.
80. Hoffman P, Mauer A, Haraf G, et al: Oral JM-216 plus concomitant radiotherapy (RT) for patients (PTS) with advanced malignancies of the chest (abstract). Proc Am Soc Clin Oncol 17:488a, 1998.
81. Taylor CW et al: Amifostine protects normal tissues from paclitaxel toxicity while cytotoxicity against tumor cells is maintained. Eur J Cancer 33:1693-1698, 1997.
82. Capizzi RL: Amifostine: The preclinical basis for broad spectrum selective cytoprotection of normal tissues from cytotoxic therapies. Semin Oncol 21(5; suppl 11):8-15, 1994.
83. Tannehill SP, Mehta MP, Larson M, et al: Effect of amifostine on toxicities associated with sequential chemotherapy for unresectable non-small-cell lung cancer: Results of a phase II trial. J Clin Oncol 15:2850-2857, 1997.
84. Roychowdhury DF, Redmond K, Desai P, et al: A phase II trial of amifostine with paclitaxel, carboplatin and concurrent radiation therapy for unresectable non-small-cell lung cancer (abstract). Proc Am Soc Clin Oncol 17:499a, 1998.
85. Evans WK, Will BP, Berthelot JM, et al: Cost of combined modality interventions for stage III non-small-cell lung cancer. J Clin Oncol 15:3038-3048, 1997.